Stay updated with breaking news from Oint Inflammation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Physicians surveyed from four different specialties reported that they were generally comfortable prescribing biosimilars, but greater discounts are needed to motivate switching patients from reference medications.
"If a patient doesn't achieve remission or very low disease activity, obtaining a radiograph doesn't change what you do … you're going to make a change anyway," Dr. Roy Fleischmann said.
A tool to identify patients with psoriasis at high risk of psoriatic arthritis appears near to clinical application.
A real-world analysis of the impact of biosimilar switches over 3 years of follow-up addresses the limitations of formal trials in assessing discontinuation rates.
Three out of four insurance plans use policies that result in significant to severe restriction of access to medications for seven autoimmune diseases, according to the analysis.